An Evolving Frontier: Endometrial Cancer Treatment-Immunotherapy After Immunotherapy, What Are The Opportunities for Immune Check-Point Inhibition Re-challenge and The Role of Pembrolizumab/Lenvatinib

Immunotherapy After Immunotherapy, What Are The Opportunities for Immune Check-Point Inhibition Re-challenge and The Role of Pembrolizumab/Lenvatinib

Back to course

Video Transcription

Video Summary

Dr. Stephanie Leroux presented data on immunotherapy opportunities in endometrial cancer, focusing on immune checkpoint inhibitors. Studies including NRG-GY018, RUBY, and DUO-E examined chemo with immunotherapy. Results showed potential benefits of immunotherapy post prior treatment, especially in MMRD patients. Trials like GOG86 highlighted the importance of biomarkers in treatment selection. Ongoing trials explore combining PD-1 inhibitors with anti-angiogenics or dual immune checkpoint inhibitors like LAG-3 and PD-1. Understanding resistance mechanisms post immunotherapy, such as primary and acute resistance, is key to developing effective treatments. Progression timing and biomarker-driven patient selection play a crucial role in designing future trials to optimize treatment strategies in endometrial cancer.

Keywords

immunotherapy

endometrial cancer

immune checkpoint inhibitors

biomarkers

PD-1 inhibitors

resistance mechanisms